One-week dose titration of extended release galantamine in patients with Alzheimer's disease

Alzheimer's and Dementia

Volumn 4, Issue 1, 2008, Pages 30-37

  Scharre, Douglas W ^a   Shiovitz, Thomas ^b   Zhu, Young ^c   Amatniek, Joan ^c  

^a OHIO STATE UNIVERSITY   (United States)

^b California Neuroscience Research Medical Group Inc   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; Dose titration; Extended release; Galantamine

Indexed keywords

ANTIDIARRHEAL AGENT; ANTIINFECTIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GALANTAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PROTON PUMP INHIBITOR; SALICYLIC ACID DERIVATIVE; THYROID HORMONE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; COGNITION; CORRELATION ANALYSIS; DECREASED APPETITE; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLANK PAIN; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HYPONATREMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PARESTHESIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCORING SYSTEM; SIDE EFFECT; SUSTAINED RELEASE FORMULATION; VOMITING; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GALANTAMINE; HUMANS; MALE; MIDDLE AGED;

EID: 38049022013     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2007.10.013     Document Type: Article

References (18)

1. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., and Evans D.A. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60 (2003) 1119-1122
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition, text revision (2000), American Psychiatric Association, Washington, DC
3. Kaufer D.I., Borson S., Kershaw P., and Sadik K. Reduction of caregiver burden in Alzheimer's disease by treatment with galantamine. CNS Spectr 10 (2005) 481-488
4. Bonner L.T., and Peskind E.R. Pharmacologic treatments of dementia. Med Clin North Am 86 (2002) 657-674
5. Trinh N.H., Hoblyn J., Mohanty S., and Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 289 (2003) 210-216
6. Olin J., and Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev 1 (2001) CD001747
7. Nordberg A., and Svensson A.L. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Saf 19 (1998) 465-480
8. Bores G.M., Huger F.P., Petko W., Mutlib A.E., Camacho F., Rush D.K., et al. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther 277 (1996) 728-738
9. Schrattenholz A., Pereira E.F., Roth U., Weber K.H., Albuquerque E.X., and Maelicke A. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol 49 (1996) 1-6
10. Samochocki M., Hoffle A., Fehrenbacher A., Jostock R., Ludwig J., Christner C., et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 305 (2003) 1024-1036
11. Zhao Q., Janssens L., Verhaeghe T., Brashear H.R., and Truyen L. Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers. Curr Med Res Opin 21 (2005) 1547-1554
12. Brodaty H., Corey-Bloom J., Potocnik F.C., Truyen L., Gold M., and Damaraju C.R. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord 20 (2005) 120-132
13. Dunbar F., Zhu Y., and Brashear H.R. Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel-group, 6-month study. Clin Ther 28 (2006) 365-372
14. Raskind M.A., Peskind E.R., Wessel T., Yuan W., and The Galantamine USA-1 Study Group. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 54 (2000) 2261-2268
15. Rockwood K., Mintzer J., Truyen L., Wessel T., and Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosug Psychiatry 71 (2001) 589-595
16. Wilcock G.K., Lilienfeld S., Gaens E., and Galantamine International-1 Study Group. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Br Med J [Clin Res] 321 (2000) 1445-1449
17. Winblad B., Brodaty H., Gauthier S., Morris J.C., Orgogozo J.M., Rockwood K., et al. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?. Int J Geriatr Psychiatry 16 (2001) 653-666
18. Doraiswamy P.M., Kaiser L., Bieber F., and Garman R.L. The Alzheimer's disease assessment scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease. Alzheimer Dis Assoc Disord 15 (2001) 174-183